Dual agonist glp-1 and neurotensin fusion peptide

A fusion peptide comprising a first peptide linked to a second peptide, which first peptide comprises the sequence:

• X1-X2-X3-X4-X5-X6-X7-X8-X9
• wherein
• X1 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β hydroxy-histidine, homohistidine, Nα-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;
• X2 is A, G, V, L, I, K, S, aminoisobutyric acid (Aib), (1-aminocyclopropyl) carboxylic acid, (1 aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1 aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;
• X3 is E, D or Q;
• X4 is G or A;
• X5 is T, V, S or I;
• X6 is F or Y;
• X7 is T, or S;
• X8 is S, V, or D;
• X9 is S, D, E, N or is not present, or
• the first peptide comprising the sequence laid out in SEQ ID NO:
• 40 or SEQ ID NO:
• 41 or SEQ ID NO:
• 42, and
• which second peptide has an amino acid sequence with at least 70% identity with any one of SEQ ID NO:24 to SEQ ID NO:31, or wherein the second peptide is selected from the list consisting of:
• X10-X11-P-X12-I-L;
• P-X10-X11-P-X12-I-L;
• K-P-X10-X11-P-X12-I-L;
• N-K-P-X10-X11-P-X12-I-L;
• E-N-K-P-X10-X11-P-X12-I-L;
• Y-E-N-K-P-X10-X11-P-X12-I-L;
• L-Y-E-N-K-P-X10-X11-P-X12-I-L;
• Q-L-Y-E-N-K-P-X10-X11-P-X12-I-L;
• or
• E-L-Y-E-N-K-P-X10-X11-P-X12-I-L
• wherein
• X10 is R or K;
• X11 is R or K;
• and
• X12 is Y, S, C or T, and wherein the fusion peptide is a dual agonist of both a glucagon like peptide 1 receptor and a neurotensin receptor.